Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide

被引:163
作者
Zhang, TC [1 ]
Cao, EH [1 ]
Li, JF [1 ]
Ma, W [1 ]
Qin, JF [1 ]
机构
[1] Acad Sinica, Inst Biophys, Beijing 100101, Peoples R China
基金
中国国家自然科学基金;
关键词
As2O3; MGC-803; cell; apoptosis; intracellular Ca2+;
D O I
10.1016/S0959-8049(99)00106-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Arsenic trioxide (As2O3), used to treat human diseases for centuries in traditional Chinese medicine, has been identified as a very effective antileukaemic agent, but its effect on solid tumours which could be more suitable for clinical treatment with arsenic compounds is still unknown. In this study, we investigated the in vitro effect of As2O3 at concentrations of 0.01-1 mu M against six human malignant cell lines, MGC-803, HIC, MCF-7, HeLa, BEL-7402 and A549 cells. As2O3 inhibited growth and induced apoptosis in these malignant cells at varying degrees, in a time dose-dependent manner. The most marked effects were seen in the gastric cancer cell line, MGC-803. In contrast, minimal growth inhibition and induction of apoptosis occurred in human embryonic pulmonary cells following treatment with As2O3 found at the same concentrations. Changes in intracellular Ca2+, following As2O3 treatment were measured by Ca2+ sensitive fluorescent probe Indo-1/AM in flow cytometric assays. The increase in intracellular Ca2+ correlated with the sensitivity of these cells to As2O3, possibly indicating that a critical intracellular Ca2+ signal transduction pathway could he involved in As2O3-mediated cell-death and its selectivity. The marked sensitivity of MGC-803 cells in vitro suggests that As2O3 may be a potential antigastric cancer agent. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1258 / 1263
页数:6
相关论文
共 20 条
[1]  
ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323
[2]  
[Anonymous], 1983, J IMMUNOL METH
[3]   ENDONUCLEASE ACTIVATION DURING APOPTOSIS - THE ROLE OF CYTOSOLIC CA2+ AND PH [J].
BARRY, MA ;
EASTMAN, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (02) :782-789
[4]  
BERGAMASCHI G, 1994, HAEMATOLOGICA, V79, P86
[5]  
Chen GQ, 1996, BLOOD, V88, P1052
[6]   Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis [J].
Chen, Z ;
Wang, ZY ;
Chen, SJ .
PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) :141-149
[7]   APOPTOSIS IN CANCER-THERAPY - CROSSING THE THRESHOLD [J].
FISHER, DE .
CELL, 1994, 78 (04) :539-542
[8]  
Huang SL, 1995, CHIN J HEMATOL, V16, P26
[9]   New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: Clinical and basic studies for the next generation [J].
Kitamura, K ;
Kiyoi, H ;
Yoshida, H ;
Tobita, T ;
Takeshita, A ;
Ohno, R ;
Naoe, T .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) :S36-S41
[10]   THE T(1517) TRANSLOCATION ALTERS A NUCLEAR-BODY IN A RETINOIC ACID-REVERSIBLE FASHION [J].
KOKEN, MHM ;
PUVIONDUTILLEUL, F ;
GUILLEMIN, MC ;
VIRON, A ;
LINARESCRUZ, G ;
STUURMAN, N ;
DEJONG, L ;
SZOSTECKI, C ;
CALVO, F ;
CHOMIENNE, C ;
DEGOS, L ;
PUVION, E ;
DETHE, H .
EMBO JOURNAL, 1994, 13 (05) :1073-1083